Can daily intake of aspirin and/or statins influence the behavior of non-muscle invasive bladder cancer? A retrospective study on a cohort of patients undergoing transurethral bladder resection

Antonio Pastore, Giovanni Palleschi, Andrea Fuschi, Luigi Silvestri, Yazan Al Salhi, Elisabetta Costantini, Alessandro Zucchi, Vincenzo Petrozza, Cosimo de Nunzio, Antonio Carbone

Research output: Contribution to journalArticle

Abstract

BACKGROUND: This study aimed to evaluate the behavior of non-muscle-invasive bladder cancer (NMIBC) in patients submitted to transurethral bladder resection (TURB) comparing subjects in chronic therapy with aspirin, statins, or both drugs to untreated ones.

METHODS: This retrospective study was conducted on 574 patients diagnosed with NMIBC who underwent TURB between March 2008 and April 2013. The study population was divided into two main groups: treated (aspirin and/or statins) and untreated. The treated group was further divided into three therapeutic subgroups: Group A (100 mg of aspirin, daily for at least two years); Group B (20 mg or more of statins, daily for at least two years); and Group C (100 mg of aspirin and 20 mg of statins together). The mean follow-up of patients was 45.06 months.

RESULTS: No significant differences were observed among the different groups at baseline. On multivariate analysis, statin treatment, smokers and high stage disease (T1) achieved the level of independent risk factor for the occurrence of a recurrence. When patients were stratified according to the different treatment; patients treated with statins (Group B) presented an higher rate of failure (56/91 patients; 61.5%) when compared to Group A (42/98 patients; 42.9%), Group C (56/98; 57.1%) and (133/287 patients; 46.3%). This difference corresponds to a significant difference in recurrence failure free survival (p = 0.01).

CONCLUSIONS: Our results suggest that long-term treatment with aspirin in patients with NMIBC might play a role on reducing the risk of tumor recurrence. In contrast, in our investigation data from statins and combination treatment groups showed increased recurrence rates. A long-term randomized prospective study could definitively assess the possible role of this widely used drugs in NMIBC.

Original languageEnglish
Pages (from-to)120
Number of pages1
JournalBMC Cancer
Volume15
DOIs
Publication statusPublished - 2015

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Urinary Bladder Neoplasms
Aspirin
Urinary Bladder
Retrospective Studies
Recurrence
Therapeutics
Pharmaceutical Preparations
Multivariate Analysis
Prospective Studies
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Can daily intake of aspirin and/or statins influence the behavior of non-muscle invasive bladder cancer? A retrospective study on a cohort of patients undergoing transurethral bladder resection. / Pastore, Antonio; Palleschi, Giovanni; Fuschi, Andrea; Silvestri, Luigi; Al Salhi, Yazan; Costantini, Elisabetta; Zucchi, Alessandro; Petrozza, Vincenzo; de Nunzio, Cosimo; Carbone, Antonio.

In: BMC Cancer, Vol. 15, 2015, p. 120.

Research output: Contribution to journalArticle

Pastore, Antonio ; Palleschi, Giovanni ; Fuschi, Andrea ; Silvestri, Luigi ; Al Salhi, Yazan ; Costantini, Elisabetta ; Zucchi, Alessandro ; Petrozza, Vincenzo ; de Nunzio, Cosimo ; Carbone, Antonio. / Can daily intake of aspirin and/or statins influence the behavior of non-muscle invasive bladder cancer? A retrospective study on a cohort of patients undergoing transurethral bladder resection. In: BMC Cancer. 2015 ; Vol. 15. pp. 120.
@article{f60ecfe1e8014a828f6b495493884f62,
title = "Can daily intake of aspirin and/or statins influence the behavior of non-muscle invasive bladder cancer? A retrospective study on a cohort of patients undergoing transurethral bladder resection",
abstract = "BACKGROUND: This study aimed to evaluate the behavior of non-muscle-invasive bladder cancer (NMIBC) in patients submitted to transurethral bladder resection (TURB) comparing subjects in chronic therapy with aspirin, statins, or both drugs to untreated ones.METHODS: This retrospective study was conducted on 574 patients diagnosed with NMIBC who underwent TURB between March 2008 and April 2013. The study population was divided into two main groups: treated (aspirin and/or statins) and untreated. The treated group was further divided into three therapeutic subgroups: Group A (100 mg of aspirin, daily for at least two years); Group B (20 mg or more of statins, daily for at least two years); and Group C (100 mg of aspirin and 20 mg of statins together). The mean follow-up of patients was 45.06 months.RESULTS: No significant differences were observed among the different groups at baseline. On multivariate analysis, statin treatment, smokers and high stage disease (T1) achieved the level of independent risk factor for the occurrence of a recurrence. When patients were stratified according to the different treatment; patients treated with statins (Group B) presented an higher rate of failure (56/91 patients; 61.5{\%}) when compared to Group A (42/98 patients; 42.9{\%}), Group C (56/98; 57.1{\%}) and (133/287 patients; 46.3{\%}). This difference corresponds to a significant difference in recurrence failure free survival (p = 0.01).CONCLUSIONS: Our results suggest that long-term treatment with aspirin in patients with NMIBC might play a role on reducing the risk of tumor recurrence. In contrast, in our investigation data from statins and combination treatment groups showed increased recurrence rates. A long-term randomized prospective study could definitively assess the possible role of this widely used drugs in NMIBC.",
author = "Antonio Pastore and Giovanni Palleschi and Andrea Fuschi and Luigi Silvestri and {Al Salhi}, Yazan and Elisabetta Costantini and Alessandro Zucchi and Vincenzo Petrozza and {de Nunzio}, Cosimo and Antonio Carbone",
year = "2015",
doi = "10.1186/s12885-015-1152-x",
language = "English",
volume = "15",
pages = "120",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",

}

TY - JOUR

T1 - Can daily intake of aspirin and/or statins influence the behavior of non-muscle invasive bladder cancer? A retrospective study on a cohort of patients undergoing transurethral bladder resection

AU - Pastore, Antonio

AU - Palleschi, Giovanni

AU - Fuschi, Andrea

AU - Silvestri, Luigi

AU - Al Salhi, Yazan

AU - Costantini, Elisabetta

AU - Zucchi, Alessandro

AU - Petrozza, Vincenzo

AU - de Nunzio, Cosimo

AU - Carbone, Antonio

PY - 2015

Y1 - 2015

N2 - BACKGROUND: This study aimed to evaluate the behavior of non-muscle-invasive bladder cancer (NMIBC) in patients submitted to transurethral bladder resection (TURB) comparing subjects in chronic therapy with aspirin, statins, or both drugs to untreated ones.METHODS: This retrospective study was conducted on 574 patients diagnosed with NMIBC who underwent TURB between March 2008 and April 2013. The study population was divided into two main groups: treated (aspirin and/or statins) and untreated. The treated group was further divided into three therapeutic subgroups: Group A (100 mg of aspirin, daily for at least two years); Group B (20 mg or more of statins, daily for at least two years); and Group C (100 mg of aspirin and 20 mg of statins together). The mean follow-up of patients was 45.06 months.RESULTS: No significant differences were observed among the different groups at baseline. On multivariate analysis, statin treatment, smokers and high stage disease (T1) achieved the level of independent risk factor for the occurrence of a recurrence. When patients were stratified according to the different treatment; patients treated with statins (Group B) presented an higher rate of failure (56/91 patients; 61.5%) when compared to Group A (42/98 patients; 42.9%), Group C (56/98; 57.1%) and (133/287 patients; 46.3%). This difference corresponds to a significant difference in recurrence failure free survival (p = 0.01).CONCLUSIONS: Our results suggest that long-term treatment with aspirin in patients with NMIBC might play a role on reducing the risk of tumor recurrence. In contrast, in our investigation data from statins and combination treatment groups showed increased recurrence rates. A long-term randomized prospective study could definitively assess the possible role of this widely used drugs in NMIBC.

AB - BACKGROUND: This study aimed to evaluate the behavior of non-muscle-invasive bladder cancer (NMIBC) in patients submitted to transurethral bladder resection (TURB) comparing subjects in chronic therapy with aspirin, statins, or both drugs to untreated ones.METHODS: This retrospective study was conducted on 574 patients diagnosed with NMIBC who underwent TURB between March 2008 and April 2013. The study population was divided into two main groups: treated (aspirin and/or statins) and untreated. The treated group was further divided into three therapeutic subgroups: Group A (100 mg of aspirin, daily for at least two years); Group B (20 mg or more of statins, daily for at least two years); and Group C (100 mg of aspirin and 20 mg of statins together). The mean follow-up of patients was 45.06 months.RESULTS: No significant differences were observed among the different groups at baseline. On multivariate analysis, statin treatment, smokers and high stage disease (T1) achieved the level of independent risk factor for the occurrence of a recurrence. When patients were stratified according to the different treatment; patients treated with statins (Group B) presented an higher rate of failure (56/91 patients; 61.5%) when compared to Group A (42/98 patients; 42.9%), Group C (56/98; 57.1%) and (133/287 patients; 46.3%). This difference corresponds to a significant difference in recurrence failure free survival (p = 0.01).CONCLUSIONS: Our results suggest that long-term treatment with aspirin in patients with NMIBC might play a role on reducing the risk of tumor recurrence. In contrast, in our investigation data from statins and combination treatment groups showed increased recurrence rates. A long-term randomized prospective study could definitively assess the possible role of this widely used drugs in NMIBC.

UR - http://www.scopus.com/inward/record.url?scp=84979854855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979854855&partnerID=8YFLogxK

U2 - 10.1186/s12885-015-1152-x

DO - 10.1186/s12885-015-1152-x

M3 - Article

C2 - 25877676

VL - 15

SP - 120

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

ER -